|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



,2
* Department of Anesthesiology,
Cellular and Molecular Medicine,
Pharmacology, University of California, San Diego, CA, USA; and
Veterans Affairs San Diego Healthcare System, San Diego, California, USA
2Correspondence: VASDHS (125), 3350 La Jolla Village Dr., San Diego, CA 92161, USA. E-mail: droth{at}ucsd.edu
Caveolae, small invaginations in the plasma membrane, contain caveolins (Cav) that scaffold signaling molecules including the tyrosine kinase Src. We tested the hypothesis that cardiac protection involves a caveolin-dependent mechanism. We used in vitro and in vivo models of ischemia-reperfusion injury, electron microscopy (EM), transgenic mice, and biochemical assays to address this hypothesis. We found that Cav-1 mRNA and protein were expressed in mouse adult cardiac myocytes (ACM). The volatile anesthetic, isoflurane, protected ACM from hypoxia-induced cell death and increased sarcolemmal caveolae. Hearts of wild-type (WT) mice showed rapid phosphorylation of Src and Cav-1 after isoflurane and ischemic preconditioning. The Src inhibitor PP2 reduced phosphorylation of Src (Y416) and Cav-1 in the heart and abolished isoflurane-induced cardiac protection in WT mice. Infarct size (percent area at risk) was reduced by isoflurane in WT (30.5±4 vs. 44.2±3, n=7, P<0.05) but not Cav-1/ mice (46.6±5 vs. 41.7±3, n=7). Cav-1/ mice exposed to isoflurane showed significant alterations in Src phosphorylation and recruitment of C-terminal Src kinase, a negative regulator of Src, when compared to WT mice. The results indicate that isoflurane modifies cardiac myocyte sarcolemmal membrane structure and composition and that activation of Src and phosphorylation of Cav-1 contribute to cardiac protection. Accordingly, therapies targeted to post-translational modification of Src and Cav-1 may provide a novel approach for such protection.Patel, H. H., Tsutsumi, Y. M., Head, B. P., Niesman, I. R., Jennings, M., Horikawa, Y. Huang, D., Moreno, A. L., Patel, P. M., Insel, P. A., Roth, D. M. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1.
Key Words: protein tyrosine kinase Src phosphorylation heart
This article has been cited by other articles:
![]() |
Y. M. Tsutsumi, Y. T. Horikawa, M. M. Jennings, M. W. Kidd, I. R. Niesman, U. Yokoyama, B. P. Head, Y. Hagiwara, Y. Ishikawa, A. Miyanohara, et al. Cardiac-Specific Overexpression of Caveolin-3 Induces Endogenous Cardiac Protection by Mimicking Ischemic Preconditioning Circulation, November 4, 2008; 118(19): 1979 - 1988. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lucchinetti, M. C. Schaub, and M. Zaugg Emulsified Intravenous Versus Evaporated Inhaled Isoflurane for Heart Protection: Old Wine in a New Bottle or True Innovation? Anesth. Analg., May 1, 2008; 106(5): 1346 - 1349. [Full Text] [PDF] |
||||
![]() |
B. P. Head, H. H. Patel, Y. M. Tsutsumi, Y. Hu, T. Mejia, R. C. Mora, P. A. Insel, D. M. Roth, J. C. Drummond, and P. M. Patel Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death FASEB J, March 1, 2008; 22(3): 828 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Salani, L. Briatore, S. Garibaldi, R. Cordera, and D. Maggi Caveolin-1 Down-Regulation Inhibits Insulin-Like Growth Factor-I Receptor Signal Transduction in H9C2 Rat Cardiomyoblasts Endocrinology, February 1, 2008; 149(2): 461 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Volonte, C. F. McTiernan, M. Drab, M. Kasper, and F. Galbiati Caveolin-1 and caveolin-3 form heterooligomeric complexes in atrial cardiac myocytes that are required for doxorubicin-induced apoptosis Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H392 - H401. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |